Radiopharm Theranostics Limited (AU:RAD) has released an update.
Radiopharm Theranostics Limited reports significant progress in its radiopharmaceutical development, with encouraging data from RAD 301 and RAD 302 studies and a successful first patient dosing in a Phase 1 trial. Studies indicate potential for safer and more effective treatment of various carcinomas by targeting αvβ6-integrin. The company’s research, which includes a comparison study showing the superiority of RAD 301 over traditional methods, underlines the promise of its diagnostic and therapeutic agents for cancers like pancreatic and non-small cell lung cancer.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.
